Takeda’s USD 4bn psoriasis pill helped clear skin in mid-stage study
A psoriasis drug that Takeda acquired last month was safe in a mid-stage placebo-controlled study.
By Kanoko Matsuyama, bloomberg
Takeda Pharmaceutical Co.’s newly purchased oral psoriasis drug was safe and effective in a mid-stage study, highlighting its potential for treating the painful, incurable skin condition.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma books multimillion-dollar loss in 2022
For subscribers
